-+ 0.00%
-+ 0.00%
-+ 0.00%

Immuneering MAPKeeper-301 Phase 3 pancreatic cancer trial abstract wins ESMO 2026 poster slot

PUBT·09/24/2026 11:31:09
Listen to the news
Immuneering MAPKeeper-301 Phase 3 pancreatic cancer trial abstract wins ESMO 2026 poster slot
  • Immuneering flagged an ongoing Phase 3 MAPKeeper-301 trial of atebimetinib with chemotherapy in first-line metastatic pancreatic cancer.
  • Trial-in-progress details will be presented in the future at ESMO Congress 2026 in Madrid on Oct. 25.
  • No clinical results were disclosed; the update signals continued late-stage development aimed at supporting a potential first-line treatment option.
  • Full abstract publication is scheduled for Oct. 19, ahead of the poster session.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240730PRIMZONEFULLFEED9832954) on September 24, 2026, and is solely responsible for the information contained therein.